Investors Purchase High Volume of Sunesis Pharmaceuticals Put Options (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS) saw some unusual options trading on Monday. Stock traders bought 5,396 put options on the stock, Analyst RN reports. This is an increase of 420% compared to the typical daily volume of 1,038 put options.
In other Sunesis Pharmaceuticals news, Director Dayton Misfeldt unloaded 743,700 shares of Sunesis Pharmaceuticals stock on the open market in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $6.64, for a total transaction of $4,938,168.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up 3.55% on Monday, hitting $7.59. The stock had a trading volume of 1,101,444 shares. Sunesis Pharmaceuticals has a 52-week low of $3.84 and a 52-week high of $7.49. The stock’s 50-day moving average is $6.47 and its 200-day moving average is $5.85. The company’s market cap is $458.8 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings data on Tuesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the previous year, the company posted $0.18 earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. On average, analysts predict that Sunesis Pharmaceuticals will post $-0.74 earnings per share for the current fiscal year.
Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.